| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From Department of Medicine IV (S.J., M.S., M.L., H.W., G.W., R.E.S.),
University of Erlangen-Nürnberg, Klinikum Nürnberg-Süd,
Nürnberg, Germany, and Department of Clinical Chemistry and Laboratory
Medicine (G.S.), University of Regensburg, Germany.
Background—Impaired
endothelium-dependent vasodilation is an early sign of
atherosclerosis in hypercholesterolemic
patients. We hypothesized that lipid-lowering therapy can improve
endothelial function and that this effect is mainly
mediated by increased bioavailability of nitric oxide (NO).
Methods and Results—In a randomized, double-blind,
placebo-controlled trial, we studied 29 patients (age, 50±12 years)
with hypercholesterolemia (LDL
cholesterol
Conclusions—Lipid-lowering therapy with fluvastatin
can improve disturbed endothelial function in
hypercholesterolemic patients compared with placebo.
This improvement is mediated by increased bioavailability of NO.
© 1998 American Heart Association, Inc.
Clinical Investigation and Reports
Increased Bioavailability of Nitric Oxide After Lipid-Lowering Therapy in Hypercholesterolemic Patients
A Randomized, Placebo-Controlled, Double-blind Study
160 mg/dL) randomly assigned to receive
either fluvastatin (40 mg twice daily; 17 patients) or
placebo (12 patients). Forearm blood flow was measured by
plethysmography before and after 24 weeks of treatment.
Endothelium-dependent vasodilation was assessed by
intra-arterial infusion of acetylcholine (ACh; 3, 12, 24,
and 48 µg/min) and basal NO synthesis rate by
intra-arterial infusion of
NG-monomethyl-L-arginine
(L-NMMA; 1, 2, and 4 µmol/min). Simultaneous
intra-arterial infusion of L-NMMA (4 µmol/min) and
ACh (12, 24, and 48 µg/min) was used to test whether any increase in
endothelium-dependent vasodilation after lipid-lowering
therapy could be blocked by this NO synthase inhibitor.
Endothelium-dependent vasodilation improved
significantly after 24 weeks of lipid-lowering therapy compared with
before therapy (ACh 24 µg/min: 240±34% before versus 347±50%
after therapy; P
0.01) and placebo (changes between
after and before therapy with ACh 24 µg/min: 108±39% for
fluvastatin versus -26±32% for placebo;
P0.05). This improvement in
endothelium-dependent vasodilation could be blocked by
simultaneous administration of L-NMMA (ACh 24 µg/min plus
L-NMMA 4 µmol/min: 170±69% before versus 219±47% after
treatment; P=NS).
Key Words: atherosclerosis • endothelium • blood flow • hypercholesterolemia • nitric oxide • vasodilation
This article has been cited by other articles:
 |
|
 |
|
  V. Rudolph, T. K. Rudolph, F. J. Schopfer, G. Bonacci, D. Lau, K. Szocs, A. Klinke, T. Meinertz, B. A. Freeman, and S. Baldus Bivalirudin Decreases NO Bioavailability by Vascular Immobilization of Myeloperoxidase J. Pharmacol. Exp. Ther., November 1, 2008; 327(2): 324 - 331. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Focardi, G. M. Dick, A. Picchi, C. Zhang, and W. M. Chilian Restoration of coronary endothelial function in obese Zucker rats by a low-carbohydrate diet Am J Physiol Heart Circ Physiol, May 1, 2007; 292(5): H2093 - H2099. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. G Casey, M. Joyce, K. Moore, C. Thompson, P. Fitzgerald, and D. J Bouchier-Hayes Two-week treatment with pravastatin improves ventriculo-vascular haemodynamic interactions in young men with type 1 diabetes Diabetes and Vascular Disease Research, March 1, 2007; 4(1): 53 - 61. [Abstract] [PDF]
|
|
|
|
 |
|
 T. W. Rice and A. B. Lumsden Optimal Medical Management of Peripheral Arterial Disease Vascular and Endovascular Surgery, August 1, 2006; 40(4): 312 - 327. [Abstract] [PDF]
|
|
|
|
 |
|
 K. Douglas, P. G. O'Malley, and J. L. Jackson Meta-Analysis: The Effect of Statins on Albuminuria Ann Intern Med, July 18, 2006; 145(2): 117 - 124. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Al-Benna, C. A. Hamilton, J. D. McClure, P. N. Rogers, G. A. Berg, I. Ford, C. Delles, and A. F. Dominiczak Low-Density Lipoprotein Cholesterol Determines Oxidative Stress and Endothelial Dysfunction in Saphenous Veins From Patients With Coronary Artery Disease Arterioscler Thromb Vasc Biol, January 1, 2006; 26(1): 218 - 223. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. G. Herman and S. Moncada Therapeutic potential of nitric oxide donors in the prevention and treatment of atherosclerosis Eur. Heart J., October 1, 2005; 26(19): 1945 - 1955. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-H. Bae, E. Bassenge, K.-Y. Kim, Y.-C. Synn, k.-R. Park, and M. Schwemmer Effects of Low-Dose Atorvastatin on Vascular Responses in Patients Undergoing Percutaneous Coronary Intervention With Stenting Journal of Cardiovascular Pharmacology and Therapeutics, July 1, 2004; 9(3): 185 - 192. [Abstract] [PDF]
|
|
|
|
 |
|
 J. Davignon and P. Ganz Role of Endothelial Dysfunction in Atherosclerosis Circulation, June 15, 2004; 109(23_suppl_1): III-27 - III-32. [Abstract] [Full Text]
|
|
|
|
 |
|
 C. R. Wolfram Kuhlmann, C. Gast, F. Li, M. Schafer, H. Tillmanns, B. Waldecker, and J. Wiecha Cerivastatin Activates Endothelial Calcium-Activated Potassium Channels and Thereby Modulates Endothelial Nitric Oxide Production and Cell Proliferation J. Am. Soc. Nephrol., April 1, 2004; 15(4): 868 - 875. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. M. Balk, J. Lau, L. C. Goudas, H. S. Jordan, B. Kupelnick, L. U. Kim, and R. H. Karas Effects of Statins on Nonlipid Serum Markers Associated with Cardiovascular Disease: A Systematic Review Ann Intern Med, October 21, 2003; 139(8): 670 - 682. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Galle and S. Seibold Has the time come to use antioxidant therapy in uraemic patients? Nephrol. Dial. Transplant., August 1, 2003; 18(8): 1452 - 1455. [Full Text] [PDF]
|
|
|
|
 |
|
 C. Binggeli, L. E. Spieker, R. Corti, I. Sudano, V. Stojanovic, D. Hayoz, T. F. Luscher, and G. Noll Statins enhance postischemic hyperemia in the skin circulation of hypercholesterolemic patients: A monitoring test of endothelial dysfunction for clinical practice? J. Am. Coll. Cardiol., July 2, 2003; 42(1): 71 - 77. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. H. Fleischmann, M. P. Schlaich, B. M. W. Schmidt, S. Oehmer, and R. E. Schmieder Hypercholesterolaemia and treatment with statins do not alter L-arginine-induced changes of renal haemodynamics Nephrol. Dial. Transplant., October 1, 2002; 17(10): 1758 - 1765. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Sanada, Y. Higashi, K. Nakagawa, M. Tsuda, I. Kodama, M. Kimura, K. Chayama, and K. Ohama Hormone Replacement Effects on Endothelial Function Measured in the Forearm Resistance Artery in Normocholesterolemic and Hypercholesterolemic Postmenopausal Women J. Clin. Endocrinol. Metab., October 1, 2002; 87(10): 4634 - 4641. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. E. Ferrier, M. H. Muhlmann, J.-P. Baguet, J. D. Cameron, G. L. Jennings, A. M. Dart, and B. A. Kingwell Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension J. Am. Coll. Cardiol., March 20, 2002; 39(6): 1020 - 1025. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. C. B. Tan, W. S. Chow, S. C. F. Tam, V. H. G. Ai, C. H. L. Lam, and K. S. L. Lam Atorvastatin Lowers C-Reactive Protein and Improves Endothelium-Dependent Vasodilation in Type 2 Diabetes Mellitus J. Clin. Endocrinol. Metab., February 1, 2002; 87(2): 563 - 568. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Sterzer, F. Meintzschel, A. Rosler, H. Lanfermann, H. Steinmetz, and M. Sitzer Pravastatin Improves Cerebral Vasomotor Reactivity in Patients With Subcortical Small-Vessel Disease Stroke, December 1, 2001; 32(12): 2817 - 2820. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Imamura, S. Biro, T. Kihara, S. Yoshifuku, K. Takasaki, Y. Otsuji, S. Minagoe, Y. Toyama, and C. Tei Repeated thermal therapy improves impaired vascular endothelial function in patients with coronary risk factors J. Am. Coll. Cardiol., October 1, 2001; 38(4): 1083 - 1088. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Asberg, A. Hartmann, E. Fjeldsa, and H. Holdaas Atorvastatin improves endothelial function in renal-transplant recipients Nephrol. Dial. Transplant., September 1, 2001; 16(9): 1920 - 1924. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. W Wilmink, M. B Twickler, J. D. Banga, G. M Dallinga-Thie, H. Eeltink, D.W. Erkelens, T. J Rabelink, and E. S Stroes Effect of statin versus fibrate on postprandial endothelial dysfunction: role of remnant-like particles Cardiovasc Res, June 1, 2001; 50(3): 577 - 582. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Martinez-Gonzalez, B. Raposo, C. Rodriguez, and L. Badimon 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibition Prevents Endothelial NO Synthase Downregulation by Atherogenic Levels of Native LDLs : Balance Between Transcriptional and Posttranscriptional Regulation Arterioscler Thromb Vasc Biol, May 1, 2001; 21(5): 804 - 809. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. John, C. Delles, J. Jacobi, M. P. Schlaich, M. Schneider, G. Schmitz, and R. E. Schmieder Rapid improvement of nitric oxide bioavailability after lipid-lowering therapy with cerivastatin within two weeks J. Am. Coll. Cardiol., April 1, 2001; 37(5): 1351 - 1358. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Babaei, P. Picard, A. Ravandi, J. C. Monge, T. C. Lee, P. Cernacek, and D. J. Stewart Blockade of endothelin receptors markedly reduces atherosclerosis in LDL receptor deficient mice: role of endothelin in macrophage foam cell formation Cardiovasc Res, October 1, 2000; 48(1): 158 - 167. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. K. Koh Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability Cardiovasc Res, September 1, 2000; 47(4): 648 - 657. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. H. Wagner, T. Kohler, U. Ruckschloss, I. Just, and M. Hecker Improvement of Nitric Oxide-Dependent Vasodilatation by HMG-CoA Reductase Inhibitors Through Attenuation of Endothelial Superoxide Anion Formation Arterioscler Thromb Vasc Biol, January 1, 2000; 20(1): 61 - 69. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. M. Landau Is Cholesterol a Risk Factor for Stroke?: No Arch Neurol, December 1, 1999; 56(12): 1521 - 1524. [Full Text] [PDF]
|
|
|
|
|
|
D. Baller, G. Notohamiprodjo, U. Gleichmann, J. Holzinger, R. Weise, and J. Lehmann Improvement in Coronary Flow Reserve Determined by Positron Emission Tomography After 6 Months of Cholesterol-Lowering Therapy in Patients With Early Stages of Coronary Atherosclerosis Circulation, June 8, 1999; 99(22): 2871 - 2875. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R A Archbold and A D Timmis Cholesterol lowering and coronary artery disease: mechanisms of risk reduction Heart, December 1, 1998; 80(6): 543 - 547. [Full Text]
|
|